Paul Purdy
About Paul Purdy
Paul Purdy serves as the Vice President and Head of Market Access at Accord BioPharma, a position he has held since 2021. He has extensive experience in the pharmaceutical industry, having previously worked in various roles at GlaxoSmithKline and Amgen over a span of two decades.
Work at Accord BioPharma
Paul Purdy has been serving as the Vice President, Head of Market Access at Accord BioPharma since 2021. In this role, he is responsible for overseeing market access strategies and initiatives that facilitate the availability of Accord's pharmaceutical products. His leadership is focused on ensuring that patients have access to necessary medications while navigating the complexities of the healthcare system.
Previous Experience in Pharmaceuticals
Prior to his current role, Paul Purdy accumulated extensive experience in the pharmaceutical industry. He worked at GlaxoSmithKline from 1992 to 2002 in various positions, including District Manager and Managed Care Specialist. He then joined Amgen, where he held multiple roles from 2002 to 2017, including National Account Director and District Manager for the Oncology Business Unit. His tenure at Amgen included responsibilities in payor and reimbursement strategies across the Mid-Atlantic region.
Education and Academic Background
Paul Purdy studied at Elon University, where he earned a Bachelor of Science degree in Business Management. His foundational education provided him with the skills necessary for his career in the pharmaceutical industry. He also attended Kaiserslautern American High School, which contributed to his early academic development.
Career Progression in Market Access
Throughout his career, Paul Purdy has focused on market access and reimbursement strategies. His roles at Amgen included Corporate Account Senior Manager and Director for the Mid-Atlantic Region, where he developed expertise in managing corporate accounts and navigating the complexities of Medicaid and managed care organizations. This experience has been instrumental in his current position at Accord BioPharma.